-
公开(公告)号:US20070010534A1
公开(公告)日:2007-01-11
申请号:US11533034
申请日:2006-09-19
申请人: Jerry Adams , Neil Johnson , Jeffrey Murray
发明人: Jerry Adams , Neil Johnson , Jeffrey Murray
IPC分类号: A61K31/513 , A61K31/506 , A61K31/4439 , C07D403/04
CPC分类号: C07D409/14 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D417/14
摘要: The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.
摘要翻译: 本发明涉及用于治疗哺乳动物疾病发生不适当,过度或不需要的血管发生和/或发生过度Tie2受体活性的新型式(I)化合物。
-
公开(公告)号:US20060183687A1
公开(公告)日:2006-08-17
申请号:US11409944
申请日:2006-04-24
申请人: Suzanne Cory , Jerry Adams , David Huang , Liam O'Connor , Andreas Strasser , Hamsa Puthalakath , Lorraine O'Reilly
发明人: Suzanne Cory , Jerry Adams , David Huang , Liam O'Connor , Andreas Strasser , Hamsa Puthalakath , Lorraine O'Reilly
CPC分类号: C07K14/4747 , A61K38/00
摘要: The present invention relates generally to novel molecules capable of, inter alia, modulating apoptosis in mammalian cells and to genetic sequences encoding same. More particularly, the present invention relates to a novel member of the Bcl-2 family of proteins, referred to herein as “Bim”, and to genetic sequences encoding same. The molecules of the present invention are useful, for example, in therapy, diagnosis, antibody generation and as a screening tool for therapeutic agents capable of modulating physiological cell death or survival and/or modulating cell cycle entry.
摘要翻译: 本发明一般涉及能够特别调节哺乳动物细胞凋亡和编码其的遗传序列的新型分子。 更具体地,本发明涉及Bcl-2家族蛋白质的新成员,本文称为“Bim”,以及编码它们的遗传序列。 本发明的分子可用于例如治疗,诊断,抗体产生以及作为能够调节生理细胞死亡或生存和/或调节细胞周期进入的治疗剂的筛选工具。
-
公开(公告)号:US20050288503A1
公开(公告)日:2005-12-29
申请号:US10525478
申请日:2003-08-26
申请人: Jerry Adams , Jeffrey Boehm , Zehong Wan
发明人: Jerry Adams , Jeffrey Boehm , Zehong Wan
IPC分类号: C07D473/10 , C07D473/34 , C07D487/04
CPC分类号: C07D487/04 , C07D473/34
摘要: Novel substituted pyrrolo[2,3-d]pyrimidin-4-yl compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
摘要翻译: 新型取代的吡咯并[2,3-d]嘧啶-4-基化合物和用作CSBP / p38激酶抑制剂治疗的组合物。
-
-